TY - JOUR
T1 - Clinical, biochemical, and genetic features of non-classical 21-hydroxylase deficiency in Japanese children
AU - Kashimada, Kenichi
AU - Ishii, Tomohiro
AU - Nagasaki, Keisuke
AU - Ono, Makoto
AU - Tajima, Toshihiro
AU - Yokota, Ichiro
AU - Hasegawa, Yukihiro
N1 - Publisher Copyright:
© 2015 The Japan Endocrine Society.
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2015/1/7
Y1 - 2015/1/7
N2 - Non-classical 21-hydroxylase defciency (NC21-OHD) is a mild form of 21-hydroxylase defciency lacking apparent symptoms of androgen excess at birth. Most NC21-OHD cases are diagnosed after the onset of puberty, while a substantial number of patients are not diagnosed during childhood. Previous studies have reported ethnic differences in the prevalence of NC21-OHD. To date, the clinical features of NC21-OHD in Japanese children have not been systemically reported. Thus, we performed 3 independent analyses: retrospective analyses of newborn screening in 2 major Japanese cities (Sapporo and Niigata) and a national surveillance collecting clinical information from pediatric endocrinologists throughout the country. During the last 10 years, one case of NC21-OHD was diagnosed by newborn screening in each city, resulting in incidences of 2.0 (95% confdence interval = 0.0–5.9) and 2.1 (0.0–6.2) per 1,000,000 in Sapporo and Niigata, respectively. We collected information from 85% of the 135 Councilors of Japanese Society of Pediatric Endocrinology. Fifteen NC21-OHD patients were diagnosed during childhood, resulting in the estimated prevalence of 0.58 (0.28–1.1) per 1,000,000. Eleven patients were discovered by newborn screening, 7 patients developed hyperandrogenism symptoms (2–8 years of age, median 7), and 9 patients were treated with hydrocortisone at the time of the survey. Ten out of 13 patients showed compound heterozygosity for the P30L mutation of CYP21A2. Our study suggests that the prevalence/incidence of NC21-OHD is lower than that in Western countries, and that the age for initial onset of androgen excess symptoms varies during the prepubertal period.
AB - Non-classical 21-hydroxylase defciency (NC21-OHD) is a mild form of 21-hydroxylase defciency lacking apparent symptoms of androgen excess at birth. Most NC21-OHD cases are diagnosed after the onset of puberty, while a substantial number of patients are not diagnosed during childhood. Previous studies have reported ethnic differences in the prevalence of NC21-OHD. To date, the clinical features of NC21-OHD in Japanese children have not been systemically reported. Thus, we performed 3 independent analyses: retrospective analyses of newborn screening in 2 major Japanese cities (Sapporo and Niigata) and a national surveillance collecting clinical information from pediatric endocrinologists throughout the country. During the last 10 years, one case of NC21-OHD was diagnosed by newborn screening in each city, resulting in incidences of 2.0 (95% confdence interval = 0.0–5.9) and 2.1 (0.0–6.2) per 1,000,000 in Sapporo and Niigata, respectively. We collected information from 85% of the 135 Councilors of Japanese Society of Pediatric Endocrinology. Fifteen NC21-OHD patients were diagnosed during childhood, resulting in the estimated prevalence of 0.58 (0.28–1.1) per 1,000,000. Eleven patients were discovered by newborn screening, 7 patients developed hyperandrogenism symptoms (2–8 years of age, median 7), and 9 patients were treated with hydrocortisone at the time of the survey. Ten out of 13 patients showed compound heterozygosity for the P30L mutation of CYP21A2. Our study suggests that the prevalence/incidence of NC21-OHD is lower than that in Western countries, and that the age for initial onset of androgen excess symptoms varies during the prepubertal period.
KW - CYP21A2
KW - Incidence
KW - Newborn screening
KW - Non-classical 21-hydroxylase defciency
KW - Prevalence
UR - http://www.scopus.com/inward/record.url?scp=84926148541&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84926148541&partnerID=8YFLogxK
U2 - 10.1507/endocrj.EJ14-0377
DO - 10.1507/endocrj.EJ14-0377
M3 - Article
C2 - 25736066
AN - SCOPUS:84926148541
SN - 0918-8959
VL - 62
SP - 277
EP - 282
JO - Endocrine journal
JF - Endocrine journal
IS - 3
ER -